EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A PANEL DISCUSSION The Summit theme “unlocking the $1 Trillion Wealth ...
The FDA agrees that the Company may follow 505(b)(2) regulatory pathway to non-invasively treat basal cell carcinoma (BCC) of the skin using dissolvable Doxorubicin-containing Microneedle arrays ...
The strong opioid painkiller tramadol is not significantly effective at easing the chronic pain for which it's widely ...
Aumolertinib had comparable efficacy to osimertinib when treating epidermal growth factor receptor ( EGFR )-mutant non-small ...
Skye Bioscience announces topline CBeyond phase 2a data from nimacimab monotherapy and combination clinical trial: San Diego Tuesday, October 7, 2025, 18:00 Hrs [IST] Skye Bioscie ...
Low-dose radiation therapy led to greater improvements in clinical outcomes vs sham irradiation in patients with mild to moderate knee OA.
For people who don’t already exercise, short bursts of deliberate activity significantly improved cardiorespiratory fitness.
The TROPION-Breast02 trial is the first to show overall survival benefit in this patient population, indicating a potential ...
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 7, 2025 /CNW/ — Equity InsiderNews Commentary – Major pharmaceutical companies presenting at the ...
Nerandomilast is the first FDA-approved treatment for IPF in over a decade, targeting lung function decline. The FDA has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback